Baseline clinical characteristics
Characteristic . | Patients with GO; N = 14 . | Patients without GO; N = 48 . | P* . |
|---|---|---|---|
| Median age, y (range) | 45 (18-52) | 40 (20-57) | .65† |
| Sex, n (%) | .76 | ||
| Male | 8 (57) | 23 (48) | |
| Female | 6 (43) | 25 (52) | |
| Diagnosis, n (%) | .18 | ||
| AML | 14 (100) | 40 (83) | |
| AML from MDS | 0 | 8 (17) | |
| Conditioning regimen, n (%) | .49 | ||
| Busulphan/cytoxan | 0 (0) | 3 (6) | |
| Cytoxan/TBI | 14 (100) | 45 (94) | |
| Donor, n (%) | .12 | ||
| Matched related | 6 (43) | 32 (67) | |
| Alternative donor | 8 (57) | 16 (33) | |
| Matched unrelated | 6 (42) | 11 (23) | |
| Mismatched | 2 (14) | 5 (10) | |
| Status at conditioning, n (%) | .99 | ||
| First CR | 4 (29) | 16 (33) | |
| More than first CR | 10 (71) | 32 (67) | |
| GVHD prophylaxis, n (%) | .99 | ||
| Tacrolimus/CD8 T-cell—depleted | 3 (21) | 13 (27) | |
| Tacrolimus ± MTX ± rapamycin | 11 (79) | 35 (73) | |
| Baseline liver function | |||
| Bilirubin, mg/dL (range) | 0.7 (0.3-1.3) | 0.6 (0.2-2.0) | .24† |
| AST, U/L (range) | 21 (6-52) | 18.5 (8-73) | .40† |
| ALT, U/L (range) | 22.5 (5-62) | 22.5 (4-195) | .78† |
Characteristic . | Patients with GO; N = 14 . | Patients without GO; N = 48 . | P* . |
|---|---|---|---|
| Median age, y (range) | 45 (18-52) | 40 (20-57) | .65† |
| Sex, n (%) | .76 | ||
| Male | 8 (57) | 23 (48) | |
| Female | 6 (43) | 25 (52) | |
| Diagnosis, n (%) | .18 | ||
| AML | 14 (100) | 40 (83) | |
| AML from MDS | 0 | 8 (17) | |
| Conditioning regimen, n (%) | .49 | ||
| Busulphan/cytoxan | 0 (0) | 3 (6) | |
| Cytoxan/TBI | 14 (100) | 45 (94) | |
| Donor, n (%) | .12 | ||
| Matched related | 6 (43) | 32 (67) | |
| Alternative donor | 8 (57) | 16 (33) | |
| Matched unrelated | 6 (42) | 11 (23) | |
| Mismatched | 2 (14) | 5 (10) | |
| Status at conditioning, n (%) | .99 | ||
| First CR | 4 (29) | 16 (33) | |
| More than first CR | 10 (71) | 32 (67) | |
| GVHD prophylaxis, n (%) | .99 | ||
| Tacrolimus/CD8 T-cell—depleted | 3 (21) | 13 (27) | |
| Tacrolimus ± MTX ± rapamycin | 11 (79) | 35 (73) | |
| Baseline liver function | |||
| Bilirubin, mg/dL (range) | 0.7 (0.3-1.3) | 0.6 (0.2-2.0) | .24† |
| AST, U/L (range) | 21 (6-52) | 18.5 (8-73) | .40† |
| ALT, U/L (range) | 22.5 (5-62) | 22.5 (4-195) | .78† |